Ultragenyx to Present at Upcoming Investor Conferences
Jayson Dallas , M.D., the company’s Chief Commercial Officer, will present at the Jefferies 2018 Global Healthcare Conference onTuesday, June 5, 2018 at3:00 pm ET inNew York .- Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the
Goldman Sachs 39th Annual Global Healthcare Conference onWednesday, June 13, 2018 at2:40 pm PT inRancho Palos Verdes, CA. Tom Kassberg , the company's Chief Business Officer, will present at theJMP Securities Life Sciences Conference onWednesday, June 20, 2018 at11:00 am ET inNew York .
The live and archived webcasts of the company’s presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcasts will be available for 90 days.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact
Investors & Media
Danielle Keatley
415-475-6876
Source: Ultragenyx Pharmaceutical Inc.